{"ORPHApacket":[{"ORPHApacketID":"398127","date":"2019-12-06 04:27:13","version":"1.3.1 \/ 4.1.7 [2019-11-24] (orientdb version)","copyright":"Orphanet (c) 2019","ORPHA":"398127","Name":[{"lang":"en","label":"Neonatal scleroderma"}],"PURL":"http:\/\/www.orpha.net\/ORDO\/Orphanet_398127","DisorderType":[{"Name":[{"lang":"en","label":"Disease"}],"PURL":"http:\/\/www.orpha.net\/ORDO\/Orphanet_377788"}],"SubClassOfList":[{"Disorder":[{"Name":[{"lang":"en","label":"Secondary neonatal autoimmune disease"}],"ORPHA":"398091","PURL":"http:\/\/www.orpha.net\/ORDO\/Orphanet_398091"}]}],"TextSection":[{"Name":[{"lang":"en","label":"Definition"}],"Contents":"Neonatal scleroderma is a very rare, secondary, neonatal autoimmune disease characterized by neonatal-onset of erythematous skin lesions with a linear appearance that gradually become indurated and hyperpigmented and progressively present skin atrophy. Positive serum antibodies (in particular antinuclear antibodies and\/or rheumatoid factor) may be associated."}],"AverageAgeOfOnsetList":[{"count":"1","AverageAgeOfOnset":[{"Name":[{"lang":"en","label":"Neonatal"}]}]}]}]}